Pathological response to neoadjuvant therapy correlates to RFS, OS in stage III melanoma


February 21, 2021

4 min read


Published by:

Disclosures: Menzies reports advisory board roles with Bristol Myers Squibb, Merck Sharp & Dohme, Novartis, Pierre Fabre and Roche. Please see the study for all other authors’ relevant financial disclosures.

Want to know more click here go to source.

From -
Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages

Site Language

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.